Patient-reported and Clinical Outcomes Among Patients Hospitalized for Heart Failure With Reduced Versus Preserved Ejection Fraction



      Differences between patients hospitalized for heart failure with reduced ejection fraction (HFrEF) vs HF with preserved EF (HFpEF) are not well-characterized, particularly as pertains to in-hospital decongestion and longitudinal patient-reported outcomes. The objective of this analysis was to compare patient-reported and clinical outcomes between patients hospitalized with HFrEF vs HFpEF.

      Methods and Results

      The Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF) trial enrolled 7141 patients hospitalized for HF with reduced or preserved EF. We assessed the association between an EF ≤ 40% vs an EF >40% with in-hospital decongestion, risk of rehospitalization and mortality, and quality of life as measured by the EuroQOL 5 Dimensions (EQ-5D). Among 5800 patients (81%) with complete EF data, 4782 (82%) had an EF ≤40% and 1018 (18%) had an EF >40%. Both groups demonstrated similar rates of decongestion by weight change and urine volume through 24 hours, a similar risk of 30-day mortality and HF rehospitalization, and a similar 180-day mortality. Patients with HFpEF had worse EQ-5D scores at hour 24 (median 0.76, [interquartile range (IQR) 0.51–0.84] vs 0.78 [IQR 0.57–0.84]; P = .01) that persisted through discharge (0.81 [IQR 0.69–0.86] vs 0.83 [IQR 0.71–1.00]; P < .001) and the 30-day follow-up (0.78 [IQR 0.60–0.85] vs 0.83 [IQR 0.71–1.00]; P < .001). After adjustment, these differences were attenuated and not statistically significant.


      In this large, multinational cohort of patients hospitalized for HF, patients with an EF ≤ 40% vs an EF >40% experienced similar in-hospital decongestion and postdischarge clinical outcomes. Patients with an EF >40% reported worse in-hospital and postdischarge patient-reported health status, but these measures were similar to HFrEF after accounting for other clinical factors.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Cardiac Failure
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Shah KS
        • Xu H
        • Matsouaka RA
        • et al.
        Heart Failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes.
        J Am Coll Cardiol. 2017; 70: 2476-2486
        • Chandra A
        • Vaduganathan M
        • Lewis EF
        • et al.
        Health-related quality of life in heart failure with preserved ejection fraction: the PARAGON-HF Trial.
        JACC Hear Fail. 2019; 7: 862-874
        • Chen X
        • Xin Y
        • Hu W
        • Zhao Y
        • Zhang Z
        • Zhou Y.
        Quality of life and outcomes in heart failure patients with ejection fractions in different ranges.
        PLoS One. 2019; 14: 1-13
        • Lewis EF
        • Lamas GA
        • O’ Meara E
        • et al.
        Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM.
        Eur J Heart Fail. 2007; 9: 83-91
        • Warraich HJ
        • Kitzman DW
        • Whellan DJ
        • et al.
        Physical function, frailty, cognition, depression, and quality of life in hospitalized adults ≥60 years with acute decompensated heart failure with preserved versus reduced ejection fraction.
        Circ Heart Fail. 2018; 11e005254
        • Ziaeian B
        • Heidenreich PA
        • Xu H
        • et al.
        Race/ethnic differences in outcomes among hospitalized Medicare patients with heart failure and preserved ejection fraction.
        JACC Heart Fail. 2017; 5: 483-493
        • Lewis EF
        • Claggett B
        • Shah AM
        • et al.
        Racial differences in characteristics and outcomes of patients with heart failure and preserved ejection fraction in the Treatment of Preserved Cardiac Function Heart Failure Trial.
        Circ Heart Fail. 2018; 11e004457
        • Gurwitz JH
        • Magid DJ
        • Smith DH
        • et al.
        The complex relationship of race to outcomes in heart failure with preserved ejection fraction.
        Am J Med. 2015; 128: 591-600
        • Greenberg B
        • O'Connor CM
        • Felker GM
        Classifying heart failure in the 21st century: matching taxonomy with science.
        JACC Hear Fail. 2021; 9: 771-773
        • O'Connor CM
        • Starling RC
        • Hernandez AF
        • et al.
        Effect of nesiritide in patients with acute decompensated heart failure.
        N Engl J Med. 2011; 365: 32-43
        • Hernandez AF
        • O'Connor CM
        • Starling RC
        • et al.
        Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF).
        Am Heart J. 2009; 157: 271-277
        • Yancy CW
        • Jessup M
        • Bozkurt B
        • et al.
        2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
        J Am Coll Cardiol. 2013; 62: e147-e239
        • McDonagh TA
        • Metra M
        • Adamo M
        • et al.
        2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure.
        Eur Heart J. 2021; 42: 3599-3726
        • McMurray JJV
        • Solomon SD
        • Inzucchi SE
        • et al.
        Dapagliflozin in patients with heart failure and reduced ejection fraction.
        N Engl J Med. 2019; 381: 1995-2008
        • Packer M
        • Anker SD
        • Butler J
        • et al.
        Cardiovascular and renal outcomes with empagliflozin in heart failure.
        N Engl J Med. 2020; 383: 1413-1424
        • Anker SD
        • Butler J
        • Filippatos G
        • et al.
        Empagliflozin in heart failure with a preserved ejection fraction.
        N Engl J Med. 2021; 385: 1451-1461
        • Blumer V
        • Greene SJ
        • Wu A
        • et al.
        Sex differences in clinical course and patient-reported outcomes among patients hospitalized for heart failure.
        JACC Heart Fail. 2021; 9: 336-345
        • Greene SJ
        • Hernandez AF
        • Dunning A
        • et al.
        Hospitalization for recently diagnosed versus worsening chronic heart failure: from the ASCEND-HF trial.
        J Am Coll Cardiol. 2017; 69: 3029-3039
        • Toma M
        • Ezekowitz JA
        • Bakal JA
        • et al.
        The relationship between left ventricular ejection fraction and mortality in patients with acute heart failure: Insights from the ASCEND-HF Trial.
        Eur J Heart Fail. 2014; 16: 334-341
        • Janwanishstaporn S
        • Feng S
        • Teerlink J
        • et al.
        Relationship between left ventricular ejection fraction and cardiovascular outcomes following hospitalization for heart failure: insights from the RELAX-AHF-2 trial.
        Eur J Heart Fail. 2020; 22: 726-738
        • Drazner MH.
        Insights from the history and physical examination in HFpEF or HFrEF: similarities and differences.
        JACC Heart Fail. 2021; 9: 398-400
        • Kolupoti A
        • Pandey A
        • Kucharska-Newton A
        • et al.
        Temporal trends and prognosis of physical exam findings in patients hospitalized with acute decompensated heart failure with preserved versus reduced ejection fraction the ARIC Study Community Surveillance.
        Circulation. 2020; 142: A13820
        • Dewan P
        • Jackson A
        • Lam CSP
        • et al.
        Interactions between left ventricular ejection fraction, sex and effect of neurohumoral modulators in heart failure.
        Eur J Heart Fail. 2020; 22: 898-901
        • Teerlink JR
        • Diaz R
        • Felker GM
        • et al.
        Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure.
        N Engl J Med. 2021; 384: 105-116

      Linked Article

      • Considerations in the Interpretation of Patient Reported Outcomes in Heart Failure with Reduced and Preserved Ejection Fraction
        Journal of Cardiac Failure
        • Preview
          Patient reported outcomes (PROs) are an important and increasingly common component of clinical research, particularly in heart failure (HF), where interest in PROs has gained ground in recent years [1]. As HF is a disease process notorious for its plethora of symptoms and vast range of available medications and therapies, PROs help focus research on patient-centered care and help balance quality of life metrics with traditional mortality reporting [2]. PROs are particularly important in HF studies that have have shown that patient preferences vary widely in terms of aggressiveness of medical treatment and time versus quality of life tradeoffs [3].
        • Full-Text
        • PDF